113979 ⎘
Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3) Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#2STABILIZER FOR URATE OXIDASE AND PEGYLATED CONJUGATE THEREOF, AND PHARMACEUTICAL USE OF STABILIZER
#3URATE OXIDASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF
#4METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#5NUCLEIC ACID DRUG FOR TREATING HYPERURICEMIA-RELATED DISEASES, PREPARATION METHOD THEREFOR, AND USE THEREOF
#6IMMUNOSUPPRESSIVE MATERIALS AND RELATED METHODS
#7METHODS OF TREATING DISEASES ASSOCIATED WITH ELEVATED URIC ACID
#8DELIVERY OF THERAPEUTIC RECOMBINANT URICASE USING NANOPARTICLES
#9METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#10DEGRADATION OF TOXINS IN VIVO
#11METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT
#12FORMULATIONS AND DOSES OF PEGYLATED URICASE
#13FORMULATIONS AND DOSES OF PEGYLATED URICASE
#14Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
#15CIRCULAR RNAS FOR EXPRESSING URATE OXIDASE, AND PREPARATION METHODS AND USES THEREOF
#16URAT1 INHIBITOR, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
#17Compositions and Methods for Enhancing Anti-Viral Therapies
#18PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT
#19MODIFIED URICASE AND USES THEREOF
#20SELF-ASSEMBLING URICASE FUSION PEPTIDES
#21URATE OXIDASE PREPARATION AND USE THEREOF
#22METHODS OF TREATING GOUT
#23Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#24URATE OXIDASE-ALBUMIN CONJUGATE, PREPARATION METHOD THEREOF, AND USE THEREOF
#25Urate oxidase-albumin conjugate, preparation method thereof, and use thereof
#26METHODS OF TREATING VIRAL INFECTIONS AND HEALTH CONSEQUENCES
#27Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
#28METHODS AND COMPOSITIONS RELATED TO COMBINED TREATMENT WITH ANTI-INFLAMMATORIES AND SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT
#29RECOMBINANT BACTERIA ENGINEERED TO TREAT DISEASES ASSOCIATED WITH URIC ACID AND METHODS OF USE THEREOF
#30INJECTABLE HIGH CONCENTRATION PHARMACEUTICAL FORMULATIONS AND METHODS OF MANUFACTURING AND USE THEREOF
#31COMBINATION THERAPIES OF PREDNISONE AND URICASE MOLECULES AND USES THEREOF
#32IMPROVED URICASE AND METHOD FOR TREATING HYPERURICEMIA USING SAME
#33STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS
#34Therapeutic Engineered Microbial Cell System and Methods for Treating Hyperuricemia and Gout
#35Variant forms of urate oxidase and use thereof
#36Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#37UOX-ALBUMIN CONJUGATE WITH CERTAIN NUMBERS OF ALBUMIN CONJUGATED THERETO, AND MANUFACTURING METHOD THEREOF
#38REDUCING IMMUNOGENICITY TO PEGLOTICASE
#39PEGLOTICASE FOR TREATMENT OF GOUT IN RENAL TRANSPLANT RECIPIENTS
#40TYROSINE DERIVATIVES AND COMPOSITIONS COMPRISING THEM
#41Uricase Derivative Co-conjugated With Fatty acid-linked PEG and optionally, Alkoxy PEG
#42PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT
#43POLYETHYLENE GLYCOL-MODIFIED URATE OXIDASE
#44URICASE GEL PREPARATION FOR EXTERNAL USE, PREPARATION METHOD THEREFOR AND USE THEREOF
#45URICASE SEQUENCES AND METHODS OF TREATMENT
#46FORMULATIONS AND DOSES OF PEGYLATED URICASE
#47Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
#48CONJUGATES OF FATTY ACID-THERAPEUTIC PROTEINS FOR HALF-LIFE EXTENSION AND USE OF THE SAME
#49Variant forms of urate oxidase and use thereof
#50Immunosuppressive materials and related methods
#51FORMULATIONS AND DOSES OF PEGYLATED URICASE
#52Drug Delivery System Comprising Nanocarrier Loaded with Urate Oxidase and Metal-Based Nanoparticle Capable of Degrading Hydrogen Peroxide and Pharmaceutical Composition Comprising the Same
#53RECOMBINANT URICASE ENZYME
#54CONJUGATES OF PROTEIN DRUGS AND P/A PEPTIDES
#55REDUCING IMMUNOGENICITY TO PEGLOTICASE
#56STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS
#57Recombinant uricase enzyme
#58PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT
#59Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#60Variant forms of urate oxidase and use thereof
#61THERAPEUTIC CELL SYSTEMS AND METHODS FOR TREATING HYPERURICEMIA AND GOUT
#62Uricase sequences and methods of treatment
#63Composition for uric acid decomposition using gold nanoparticles
#64POLYMER CONJUGATES HAVING REDUCED ANTIGENICITY AND METHODS OF USING THE SAME
#65POLYMER CONJUGATES HAVING REDUCED ANTIGENICITY AND METHODS OF USING THE SAME
#66Methods and compositions related to combined treatment with antiinflammatories and synthetic nanocarriers comprising an immunosuppressant
#67Mutant-type uricase, PEG modified mutant-type uricase, and application thereof
#68Uricase sequences and methods of treatment
#69AGGREGATE-FREE URATE OXIDASE FOR PREPARATION OF NON-IMMUNOGENIC POLYMER CONJUGATES
#70Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during PEGylated uricase therapy
#71Variant forms of urate oxidase and use thereof
#72Variant forms of urate oxidase and use thereof
#73Variant forms of urate oxidase and use thereof
#74VARIANT FORMS OF URATE OXIDASE AND USE THEREOF
#75VARIANT FORMS OF URATE OXIDASE AND USE THEREOF
#76Stabilization of Aqueous Compositions of Proteins With Displacement Buffers
#77POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF
#78PURIFICATION OF PROTEINS WITH CATIONIC SURFACTANT
#79METHODS AND KITS FOR PREDICTING INFUSION REACTION RISK AND ANTIBODY-MEDIATED LOSS OF RESPONSE BY MONITORING SERUM URIC ACID DURING PEGYLATED URICASE THERAPY
#80PEG-urate oxidase conjugates and use thereof
#81Variant forms of urate oxidase and use thereof
#82Method of reducing levels of uric acid
#83Pegylated analogue protein or canine urate oxidase, preparation method and use thereof
#84Variant forms of urate oxidase and use thereof
#85PEG-urate oxidase conjugates and use thereof
#86Variant forms of urate oxidase and use thereof
#87Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
#88Humanized recombinant uricase and mutants thereof
#89Variant form of urate oxidase and use thereof
#90PEG-Urate Oxidase Conjugates and Use Thereof
#91Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof
#92USE OF IL-1 ANTAGONISTS TO TREAT PSEUDOGOUT
#93Variant form of urate oxidase and use thereof
#94Method for the preventing and/or treating IL-1 beta lung pathology in mammals by administering a uric acid reducing compound
#95Variant form of urate oxidase and use thereof
#96URICASE COMPOSITIONS AND METHODS OF USE
#97Variant form of urate oxidase and use thereof
#98Polysaccharide-protein conjugates reversibly coupled via imine bonds
#99Use of IL-1 antagonists to treat gout
#100PEG-Urate Oxidase Conjugates and Use Thereof
#101PEG-urate oxidase conjugates and use thereof
#102USE OF URATE OXIDASE FOR THE TREATMENT OR PROPHYLAXIS OF DISORDERS OR INDIRECT SEQUELAE OF THE HEART CAUSED BY ISCHEMIC OR REPERFUSION EVENTS
#103Use of IL-1 antagonists to treat gout
#104STABILIZATION OF AQUEOUS COMPOSITIONS OF PROTEINS WITH DISPLACEMENT BUFFERS
#105Purification of proteins with cationic surfactant
#106Variant form of urate oxidase and use thereof
#107Variant forms of urate oxidase and use thereof
#108Use of IL-1 antagonists to treat gout
#109Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
#110PEG-urate oxidase conjugates and use thereof
#111Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
#112Systems and methods related to degradation of uremic toxins
#113Systems and methods related to degradation of uremic toxins
#114Aggregate-free protein compositions and methods of preparing same